Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Chronic Heart Failure Clinical Practice Guidelines’ Class 1-A Pharmacologic Recommendations: Start-to-End Synergistic Drug Therapy?

Chronic Heart Failure Clinical Practice Guidelines’ Class 1-A Pharmacologic Recommendations:... DOI 10.7603/s40602-016-0004-5 ASEAN Heart Journal Vol. 24, no.1, 79 – 90 (2016) http://www .globalsciencejournals.com/journal/40602 ISSN: 2315-4551 Review Chronic Heart Failure Clinical Practice Guidelines’ Class 1-A Pharmacologic Recommendations: Start-to-End Synergistic Drug Therapy? Ramon F. Abarquez, Jr., MD; Paul Ferdinand M. Reganit, MD, MPH Carmen N. Chungunco, MD; Jean Alcover, MD; Felix Eduardo R. Punzalan, MD Eugenio B. Reyes, MD, Elleen L.Cunanan, MD Section of Cardiology, Department of Medicine, University of the Philippines, College of Medicine and Philippine General Hospital, Manila © The Author(s) 2016. This article is published with open access by ASEAN Federation of Cardiology. ABSTRACT Background: Chronic heart failure (HF) disease as an emerging epidemic has a high economic-psycho-social burden, hospitalization, readmission, morbidity and mortality rates despite many clinical practice guidelines’ evidenced-based and consensus driven recommendations that include trials’ initial-baseline data. Objective: To show that the survival and hospitalization-free event rates in the reviewed chronic HF clinical practice guidelines’ class I-A recommendations as initial HF drug therapy (IDT) is possibly a combination and ‘start-to-end’ synergistic effect of the add-on (‘end’) HF drug therapy (ADT) to the baseline (‘start’) HF drug therapy (BDT). Methodology: The references cited in the chronic HF clinical practice guidelines of the 2005, 2009, and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png ASEAN Heart Journal Springer Journals

Chronic Heart Failure Clinical Practice Guidelines’ Class 1-A Pharmacologic Recommendations: Start-to-End Synergistic Drug Therapy?

Loading next page...
 
/lp/springer-journals/chronic-heart-failure-clinical-practice-guidelines-class-1-a-MDeqeb3pDC

References (240)

Publisher
Springer Journals
Copyright
Copyright © 2016 by ASEAN Federation of Cardiology
Subject
Medicine & Public Health; Cardiology
eISSN
2315-4551
DOI
10.7603/s40602-016-0004-5
Publisher site
See Article on Publisher Site

Abstract

DOI 10.7603/s40602-016-0004-5 ASEAN Heart Journal Vol. 24, no.1, 79 – 90 (2016) http://www .globalsciencejournals.com/journal/40602 ISSN: 2315-4551 Review Chronic Heart Failure Clinical Practice Guidelines’ Class 1-A Pharmacologic Recommendations: Start-to-End Synergistic Drug Therapy? Ramon F. Abarquez, Jr., MD; Paul Ferdinand M. Reganit, MD, MPH Carmen N. Chungunco, MD; Jean Alcover, MD; Felix Eduardo R. Punzalan, MD Eugenio B. Reyes, MD, Elleen L.Cunanan, MD Section of Cardiology, Department of Medicine, University of the Philippines, College of Medicine and Philippine General Hospital, Manila © The Author(s) 2016. This article is published with open access by ASEAN Federation of Cardiology. ABSTRACT Background: Chronic heart failure (HF) disease as an emerging epidemic has a high economic-psycho-social burden, hospitalization, readmission, morbidity and mortality rates despite many clinical practice guidelines’ evidenced-based and consensus driven recommendations that include trials’ initial-baseline data. Objective: To show that the survival and hospitalization-free event rates in the reviewed chronic HF clinical practice guidelines’ class I-A recommendations as initial HF drug therapy (IDT) is possibly a combination and ‘start-to-end’ synergistic effect of the add-on (‘end’) HF drug therapy (ADT) to the baseline (‘start’) HF drug therapy (BDT). Methodology: The references cited in the chronic HF clinical practice guidelines of the 2005, 2009, and

Journal

ASEAN Heart JournalSpringer Journals

Published: Mar 8, 2016

There are no references for this article.